Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more
Korean Drug Co. Ltd - Asset Resilience Ratio
Korean Drug Co. Ltd (014570) has an Asset Resilience Ratio of 12.77% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Korean Drug Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Korean Drug Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.14 Billion | 12.77% |
| Total Liquid Assets | ₩12.14 Billion | 12.77% |
Asset Resilience Insights
- Moderate Liquidity: Korean Drug Co. Ltd has 12.77% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Korean Drug Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Korean Drug Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198 |
Drug Manufacturers - General | 0.00% |
|
PharmGen Science Inc
KO:004720 |
Drug Manufacturers - General | 0.16% |
Annual Asset Resilience Ratio for Korean Drug Co. Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Korean Drug Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.33% | ₩18.96 Billion | ₩88.89 Billion | +2.78pp |
| 2023-12-31 | 18.55% | ₩16.64 Billion | ₩89.71 Billion | -9.21pp |
| 2022-12-31 | 27.76% | ₩26.23 Billion | ₩94.52 Billion | -3.52pp |
| 2021-12-31 | 31.28% | ₩27.72 Billion | ₩88.61 Billion | +4.80pp |
| 2020-12-31 | 26.48% | ₩22.07 Billion | ₩83.34 Billion | +11.50pp |
| 2019-12-31 | 14.98% | ₩11.36 Billion | ₩75.85 Billion | +3.16pp |
| 2018-12-31 | 11.82% | ₩8.62 Billion | ₩72.96 Billion | +7.10pp |
| 2017-12-31 | 4.71% | ₩3.15 Billion | ₩66.79 Billion | -1.58pp |
| 2016-12-31 | 6.30% | ₩3.99 Billion | ₩63.41 Billion | +5.71pp |
| 2015-12-31 | 0.59% | ₩350.05 Million | ₩59.20 Billion | +0.58pp |
| 2014-12-31 | 0.01% | ₩4.68 Million | ₩62.17 Billion | -- |